drugset / Trial / NCT01358071
Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this randomized phase II trial is to compare progression-free survival (PFS) in patients randomized to NGR-hTNF plus an anthracycline versus patients randomized to an anthracycline alone
Timeline
- Start
- 2011-06
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 50 mg/m² iv every 4 weeks until confirmed evidence of disease progression | Unknown | 50 mg/m2 | Intravenous |
| Subject | 60 mg/m² iv every 3 weeks for a maximum of 8 cycles | Unknown | 60 mg/m2 | Intravenous |
| Subject | NGR-hTNF | Protein / enzyme biologic | 0.8 ug/m2 | Intravenous |